Limitation of the excessive extracellular matrix turnover is a major determinant of the beneficial effect of spironolactone on survival in patients with CHF: Insights from the RALES trial. - Zannad, F.; Alla, F.; Dousset, B.; Pitt, B. (European Journal of Heart Failure, 2000)